vs
Side-by-side financial comparison of Blue Foundry Bancorp (BLFY) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Blue Foundry Bancorp is the larger business by last-quarter revenue ($13.3M vs $9.1M, roughly 1.5× Protalix BioTherapeutics, Inc.). Blue Foundry Bancorp runs the higher net margin — -27.4% vs -60.3%, a 33.0% gap on every dollar of revenue. On growth, Blue Foundry Bancorp posted the faster year-over-year revenue change (34.2% vs -49.9%). Over the past eight quarters, Blue Foundry Bancorp's revenue compounded faster (16.0% CAGR vs -6.7%).
Blue Foundry Bancorp is a regional bank holding company based in New Jersey, United States. It offers a comprehensive range of personal and commercial banking products, including deposit accounts, consumer loans, mortgage services, and business financing solutions, serving local individual consumers and small to medium-sized enterprises.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
BLFY vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $9.1M |
| Net Profit | $-3.5M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | — | -51.1% |
| Net Margin | -27.4% | -60.3% |
| Revenue YoY | 34.2% | -49.9% |
| Net Profit YoY | -30.6% | -184.8% |
| EPS (diluted) | $-0.18 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | $9.1M | ||
| Q3 25 | $12.6M | $17.9M | ||
| Q2 25 | $12.0M | $15.7M | ||
| Q1 25 | $11.1M | $10.1M | ||
| Q4 24 | $9.9M | $18.2M | ||
| Q3 24 | $9.5M | $18.0M | ||
| Q2 24 | $10.1M | $13.5M | ||
| Q1 24 | $9.9M | — |
| Q4 25 | $-3.5M | $-5.5M | ||
| Q3 25 | $-1.9M | $2.4M | ||
| Q2 25 | $-2.0M | $164.0K | ||
| Q1 25 | $-2.7M | $-3.6M | ||
| Q4 24 | $-2.7M | $6.5M | ||
| Q3 24 | $-4.0M | $3.2M | ||
| Q2 24 | $-2.3M | $-2.2M | ||
| Q1 24 | $-2.8M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | — | -18.0% | ||
| Q1 24 | — | — |
| Q4 25 | -27.4% | -60.3% | ||
| Q3 25 | -14.8% | 13.2% | ||
| Q2 25 | -16.2% | 1.0% | ||
| Q1 25 | -24.2% | -35.8% | ||
| Q4 24 | -28.4% | 35.6% | ||
| Q3 24 | -42.7% | 18.0% | ||
| Q2 24 | -23.2% | -16.4% | ||
| Q1 24 | -28.8% | — |
| Q4 25 | $-0.18 | $-0.06 | ||
| Q3 25 | $-0.10 | $0.03 | ||
| Q2 25 | $-0.10 | $0.00 | ||
| Q1 25 | $-0.13 | $-0.05 | ||
| Q4 24 | $-0.12 | $0.10 | ||
| Q3 24 | $-0.19 | $0.03 | ||
| Q2 24 | $-0.11 | $-0.03 | ||
| Q1 24 | $-0.13 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.1M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $312.7M | $48.2M |
| Total Assets | $2.2B | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.1M | $14.7M | ||
| Q3 25 | $44.1M | $13.6M | ||
| Q2 25 | $41.9M | $17.9M | ||
| Q1 25 | $46.2M | $19.5M | ||
| Q4 24 | $42.5M | $19.8M | ||
| Q3 24 | $76.1M | $27.4M | ||
| Q2 24 | $60.3M | $23.4M | ||
| Q1 24 | $53.8M | — |
| Q4 25 | $312.7M | $48.2M | ||
| Q3 25 | $314.4M | $52.9M | ||
| Q2 25 | $321.3M | $49.9M | ||
| Q1 25 | $326.7M | $45.2M | ||
| Q4 24 | $332.2M | $43.2M | ||
| Q3 24 | $339.3M | $32.4M | ||
| Q2 24 | $345.6M | $28.6M | ||
| Q1 24 | $350.2M | — |
| Q4 25 | $2.2B | $82.3M | ||
| Q3 25 | $2.2B | $82.3M | ||
| Q2 25 | $2.1B | $78.5M | ||
| Q1 25 | $2.1B | $73.9M | ||
| Q4 24 | $2.1B | $73.4M | ||
| Q3 24 | $2.1B | $61.6M | ||
| Q2 24 | $2.0B | $91.5M | ||
| Q1 24 | $2.0B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.0M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.0M | $2.0M | ||
| Q3 25 | $-255.0K | $-3.7M | ||
| Q2 25 | $2.0M | $-5.2M | ||
| Q1 25 | $-3.8M | $-5.1M | ||
| Q4 24 | $5.1M | $4.0M | ||
| Q3 24 | $-3.7M | $4.1M | ||
| Q2 24 | $14.1M | $-3.6M | ||
| Q1 24 | $-4.9M | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | $4.9M | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | $-4.9M | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | 49.8% | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | -49.3% | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | 1.4% | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLFY
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
